Listing analysis and research matching spinouts:
Funding research and development through spin-outs
In a bid to cut costs AstraZeneca is spinning out its efforts to find new drugs for gastrointestinal (GI) disorders to a new company called Albireo. Part of the decision reflects AztraZeneca's recent problems with its drug, Nexium, an ulcer treatment, which has been declining in profit and its decision to direct its energies on respiratory, cancer and infectious diseases.
